Vaccines containing ribavirin and methods of use thereof

Details Vaccines containing ribavirin and methods of use thereof Vaccines containing ribavirin and methods of use thereof

2005-02-22

2005-02-22

Housel, James (Department: 1648)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S043000, C514S046000, C514S023000, C514S027000, C536S023700, C536S023720, C536S028600, C536S028700, C536S029100, C536S002000, C424S093100, C424S185100, C424S189100, C424S192100, C424S228100, C424S196110, C435S091100, C435S091210, C435S091300, C435S091310, C435S091330, C435S320100, C705S002000

Reexamination Certificate

active

06858590

ABSTRACT:
Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope present in Hepatitis C virus (HCV), are disclosed for use in treating and preventing disease, preferably HCV infection.

REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4950647 (1990-08-01), Robins et al.
patent: 5350671 (1994-09-01), Houghton et al.
patent: 5371017 (1994-12-01), Houghton et al.
patent: 5372928 (1994-12-01), Miyamura et al.
patent: 5585258 (1996-12-01), Houghton et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5597691 (1997-01-01), Houghton et al.
patent: 5670152 (1997-09-01), Weiner et al.
patent: 5670153 (1997-09-01), Weiner et al.
patent: 5679342 (1997-10-01), Houghton et al.
patent: 5683864 (1997-11-01), Houghton et al.
patent: 5698390 (1997-12-01), Houghton et al.
patent: 5712087 (1998-01-01), Houghton et al.
patent: 5712088 (1998-01-01), Houghton et al.
patent: 5712145 (1998-01-01), Houghton et al.
patent: 5714596 (1998-02-01), Houghton et al.
patent: 5728520 (1998-03-01), Weiner et al.
patent: 5756312 (1998-05-01), Weiner et al.
patent: 5767097 (1998-06-01), Tam
patent: 5856437 (1999-01-01), Miyamura et al.
patent: 5863719 (1999-01-01), Houghton et al.
patent: 5871903 (1999-02-01), Miyamura et al.
patent: 5885799 (1999-03-01), Houghton et al.
patent: 5932556 (1999-08-01), Tam
patent: 5942234 (1999-08-01), Ralston et al.
patent: 5959092 (1999-09-01), Ralston et al.
patent: 5968775 (1999-10-01), Houghton et al.
patent: 5989905 (1999-11-01), Houghton et al.
patent: 6027729 (2000-02-01), Houghton et al.
patent: 6056961 (2000-05-01), Lavie et al.
patent: 6060068 (2000-05-01), Doyle et al.
patent: 6063380 (2000-05-01), Chedid et al.
patent: 6063772 (2000-05-01), Tam
patent: 6071693 (2000-06-01), Cha et al.
patent: 6074816 (2000-06-01), Houghton et al.
patent: 6074846 (2000-06-01), Ralston et al.
patent: 6074852 (2000-06-01), Ralston et al.
patent: 6096541 (2000-08-01), Houghton et al.
patent: 6130326 (2000-10-01), Ramasamy et al.
patent: 6150087 (2000-11-01), Chien
patent: 6150337 (2000-11-01), Tam
patent: 6171782 (2001-01-01), Houghton et al.
patent: 6190864 (2001-02-01), Cha et al.
patent: 6194140 (2001-02-01), Houghton et al.
patent: 6214583 (2001-04-01), Cha et al.
patent: 6235888 (2001-05-01), Pachuk et al.
patent: 6274148 (2001-08-01), Ralston et al.
patent: 6297370 (2001-10-01), Cha et al.
patent: 6303292 (2001-10-01), Weiner et al.
patent: 6312889 (2001-11-01), Houghton et al.
patent: 6514731 (2003-02-01), Valenzuela et al.
patent: 6541011 (2003-04-01), Punnonen et al.
patent: 6555114 (2003-04-01), Maertens et al.
patent: 20020004048 (2002-01-01), Ralston et al.
patent: 20020165172 (2002-11-01), Sallberg et al.
patent: 20020183508 (2002-12-01), Maertens et al.
patent: 20020187945 (2002-12-01), Tam
patent: 20030007977 (2003-01-01), Wheeler et al.
patent: 20030008274 (2003-01-01), Maeterns et al.
patent: 20030032005 (2003-02-01), Maertens et al.
patent: 20030044774 (2003-03-01), Valenzuela et al.
patent: 20030064360 (2003-04-01), Maertens et al.
patent: 0 388 232 (1990-09-01), None
patent: 0 414 475 (1991-02-01), None
patent: 0 450 931 (1996-06-01), None
patent: 0 543 924 (1997-06-01), None
patent: 0 842 947 (1998-05-01), None
patent: 0 693 687 (1999-07-01), None
patent: 0 556 292 (1999-12-01), None
patent: 1 034 785 (2000-09-01), None
patent: 0 318 216 (2001-08-01), None
patent: 0 398 748 (2002-01-01), None
patent: WO 9115575 (1991-10-01), None
patent: WO 9219743 (1992-11-01), None
patent: WO 9300365 (1993-01-01), None
patent: WO 9306126 (1993-04-01), None
patent: WO 9416737 (1994-08-01), None
patent: WO 9628162 (1996-09-01), None
patent: WO 9712043 (1997-04-01), None
patent: WO 9726883 (1997-07-01), None
patent: WO 9816184 (1998-04-01), None
patent: WO 9816186 (1998-04-01), None
patent: WO 9830223 (1998-07-01), None
patent: WO 0044388 (2000-08-01), None
patent: WO 0213855 (2002-02-01), None
patent: WO 0214362 (2002-02-01), None
Lohman et al. Science 1999, vol. 285, pp. 110-113.*
Forns et al. PNAS 2000, vol. 97, pp. 13318-13323.*
Encke et al. Intervirology 1999, vol. 42, pp. 117-124.*
Hultgren et al. J. Gene. Virol. 1998, vol. 79, pp. 2381-2391.*
AASLD Abstracts 940, “Hepatitis C Virus NS5A Sequence Configuration does not Predict Response to Induction Interferon Plus Ribavinn,” Hepatology, p. 394A (2000).
Abrignani et al., “Perspectives for a vaccine against hepatitis C virus,” Journal of Hepatology, 31: (suppl. 1 ):259-263 (1999).
Bartenschlager et al., “Substrate Determinants for Cleavage in cis and in trans by the Hapatitis C Virus NS3 Proteinase,”Journal of Virology, pp. 198-205, (1995).
Chiang at al., “Enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response by ribavirin correlates with the increased level of IL-2,”Vaccine Strategies Against Microbial Pathogens, 42.11-42.16, p. A949 (date unknown).
Cotonat et al., “Pilot Study of Combination Therapy with Ribavirin and Interferon Alfa for the Retreatment of Chronic Hepatitis B e Antibody-Positive Patients”,Hepatology, 31(2):502-506 (2000).
Encke et al., “Genetic Immunization Generates Cellular and Humoral Immune Responses Against the Nonstructural Proteins of the Hepatitis C Virus in a Murine Model”,Journal of Immunology, 161:4917-4923 (1998).
Fang et al., “Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the Increased IL-12 level,”Journal of Hepatology, 33(5):791-798 (2000).
Grakoui et al., “A second hepatitis C virus-encoded proteinase,”Proc. Natl. Acad. Sci USA, 90:10583-10587, (1993).
Hsu et al., “Prospects for a Hepatitis C Virus Vaccine”,Clin Liver Dis, 3(4):901-915 (1999).
Kumar et al, “Sequence, expression and reconstitution of an HCV genome from a British isolate derived from a single blood donation,”Journal of Viral Hepatitis, 7:459-465 (2000).
Memar 0. et al., “Antiviral Agents in Dermatology; Current Status and Future Prospects,”Internation Journal of Dermatology, 34(9):597-606 (1995).
Proust B. et al., “Two Successive Hepatitis C Virus Infections in an Intravenous Drug User,”Journal of Clinical Microbiology, 38(8):3125-3127 (2000).
Ramasamy et al., “Monocyclic L-Nucleosides with Type 1 Cytokine-Inducing Activity,”Journal of Medicinal Chemistry, 43(5):1019-1028 (2000).
Schulof R. S., “Clinical, Virologic, and Immunologic Effects of Combination Therapy with Ribavirin and Isoprinosine in HIV-lnfected Homosexual Men,”Journal of Acquired Immune Deficiency Syndromes. 3(5):485-492 (1990).
Spector et al., “The Antviral Effect of Zidovudine and Ribavirin in Clinical Trials and the Use of p24 Antigen Levels as a Virologic Marker,”Journal of Infectious Diseases, 159(5):822-828 (1989).
Tam et al., “Ribavirin Polarizes Human T Cell Responses Towards a Type 1 Cytokine Profile,”Journal of Hepatology, 30(3):376-382 (1999) (Abstract).
Tam et al., “The Immunomodulatory effects of ribavirin: Recent findings,”International Antiviral News, 7/6:99-100 (1999).
Walsh et al., “Update on chronic viral hepatitis”,Postgrad Medical Journal, 77(910):498-505 (2001).
Wang et al., “Synthesis and Cytokine Modulation Properties of Pyrrolo[2,3,-d]-4-pyrimidone Nucleosides,”J. Med. Chem., 43(13):2566.2574 (2000).
Http://www.msi.com/life/products/cerius2/modules/analogbuilder.html, C2 Analog Builder, Jul. 6, 2000.
Zhang et al., “Interferonα Treatment Induces Delayed CD4 Proliferative Responses to the Hepatitis C Virus Nonstructural Protein 3 Regardless of the Outcome of Therapy,”The Journal of Infectious Diseases, 175:1294-1301 (1997).
Chen et al., “Human and Murine Antibody Recognition is Focused on the ATPase/Helicase, but not the Protease Domain of the Hepatitis

Affiliated with

Also associated with

Rating

Vaccines containing ribavirin and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccines containing ribavirin and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccines containing ribavirin and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3469511